Objective: Two chromosomal instability (CIN) pathways are described in glioblastoma multiforme (GBM), type 1 and type 2, which can be observed in up to 70% of the cases. Microsatellite instability (MSI) plays a pathogenic role in sporadic cancers such as colon, gastric and endometrial carcinomas with deficient mismatch repair (MMR). We aimed to perform a comprehensive analysis of the relationship between CIN and MSI mechanisms in sporadic glioblastomas. Methods: 129 GBMs were examined (109 newly diagnosed and 20 relapses) investigating MSI, immunohistochemical expression of MMR proteins as well as sequencing and promoter methylation of hMLH1. We characterized the molecular changes frequently correlated with CIN in MSI+ GBMs and compared them with 26 microsatellite-stable tumors. Results: Low-level MSI was observed in 11 of 129 (8.5%) cases and was higher in relapses than in primary GBMs (25 vs. 5.5%, p = 0.027). High-level MSI was not found in any case. A deficient expression of MLH1 and PMS2 without hMLH1 inactivation was observed only in one giant cell GBM. 55% of the MSI+ GBMs showed a profile which did not correspond to one of the known CIN pathways. An inverse association was observed between MSI and mutations of both p53 and PTEN. Conclusions: Our data suggest that CIN and MSI contribute to the genomic instability in GBMs via independent pathways. Since MSI was significantly more frequent in relapses, it might play a role in the malignant progression of GBM.

Keywords:
Glioblastoma multiforme, Tumorigenesis, Mismatch repair, Chromosomal instability
1.
Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. Nature 1998;396:643–649.
2.
Kinzler KW, Vogelstein B: Cancer susceptibility genes. Gatekeepers and caretakers. Nature 1997;386:761–763.
3.
Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK: The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215–225.
4.
Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R: A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection and survival. J Neurosurg 2001;95:190–198.
5.
Von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19–26.
6.
Von Deimling A, Louis DN, Wiestler OD: Molecular pathways in the formation of gliomas. Glia 1995;15:328–338.
7.
Reifenberger G, Liu L, Ichimura K, Schmidt KK, Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993;53:2736–2739.
8.
Lang F, Miller D, Koslow M, Newcomb E: Pathways leading to glioblastoma multiforme: A molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 1994;81:427–436.
9.
Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Deimling A: Association of gene amplification and CDKN2A (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 1997;7:871–875.
10.
Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7:755–764.
11.
Collins VP: Gliomas. Cancer Surv 1998;32:37–51.
12.
Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 1993;260:816–819.
13.
Ionov Y, Peinado A, Malkhosyan D, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558–561.
14.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M: Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997;275:967–969.
15.
Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Wakatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KN, Meltzer SJ, Horii A: PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17:143–144.
16.
Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, Järvinen H, Powell SM, Hamilton SR: Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812–816.
17.
Lothe RA, Peltomaki P, Meling GI, Aaltonen LA, Nystrom-Lahti M, Pylkkanen L, Heimdal K, Andersen TI, Moller P, Rognum TO: Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res. 1993;53:5849–5852.
18.
Caduff RF, Johnston CM, Svoboda-Newman SM, Poy EL, Merajver SD, Frank TS: Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol 1996;148:1671–1678.
19.
Renault B, Calistri D, Buonsanti G, Nanni O, Amadosi D, Ranzani GN: Microsatellite instability and mutations of p53 and TGF-βRII genes in gastric cancers: Hum Genet 1996;98:601–607.
20.
Field JK, Kiaris H, Howard P, Vaughan ED, Spandidos DA, Jones AS: Microsatellite instability in squamous cell carcinoma of the head and neck. Br J Cancer 1995;71:1065–1069.
21.
Wooster R, Cleton-Jansen AM, Collins VP, Mangion J, Cornelis RS, Cooper CS, von Deimling A, Wiestler OD, Stratton MR: Instability of short tandem repeats (microsatellites) in human cancer. Nat Genet 1994;6:152–156.
22.
Watanabe M, Imai H, Kato H, Shiraishi T, Ushijima T, Nagao M, Yatani R: Microsatellite instability in latent prostate cancers. Int J Cancer 1996;69:394–397.
23.
Kane MF, Loda M, Gaida G, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R: Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808–811.
24.
Cottu PH, Muzeau F, Estreicher A, Flejou JF, Iggo R, Thomas G, Hamelin R: Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines. Oncogene 1996;13:2727–2730.
25.
Kim JJ, Baek MJ, Kim L, Kim NG, Lee YC, Song SY, Noh SH, Kim H: Accumulated frameshift mutations at coding nucleotide repeats during the progression of gastric carcinoma with microsatellite instability. Lab Invest 1999;79:1113–1120.
26.
Strickler JG, Zheng J, Shu Q, Burgart LJ, Alberts SR, Shibata D: p53 mutations and microsatellite instability in sporadic gastric cancer: when guardians fail. Cancer Res 1994;54:4750–4755.
27.
Boland R, Thibodeau S, Hamilton S, Sidransky D, Eshleman J, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava SA: National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination for microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248–5257.
28.
Dietmaier W, Wallinger S, Bocker T, Kullman F, Fishel R, Ruschoff J: Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression. Cancer Res 1997;57:4749–4756.
29.
Plaschke J, Kruppa C, Tischler R, Bocker T, Pistorius S, Dralle H, Rüschoff J, Saeger HD, Fishel R, Schackert HK: Sequence analysis of the mismatch repair gene hMSH6 in the germline of patients with familial and sporadic colorectal cancer. Int J Cancer 2000;85:606–613.
30.
Oda S, Oki E, Maehara Y, Sugimachi K: Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Res 1997;25:3415–3420.
31.
Cawkwell L, Lewis FA, Quirke P: Frequency of allele loss of DCC, p53, RB1, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer 1994;70:813–818.
32.
Hahn M, Wieland I, Koufaki ON, Görgens H, Sobottka SB, Schackert G, Schackert HK: Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases. Clin Cancer Res 1999;5:2431–2437.
33.
Thibodeau SN, French AJ, Cunningham JM, Teter D, Burgart LJ, Roche PC, McDonnell SK, Schaid DJ, Vockley CW, Michels VV, Farr GH Jr., Connell MJ: Microsatellite instability in colorectal cancers: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res 1998;58:1713–1718.
34.
Plaschke J, Kruger S, Pistorius S, Theissig F, Saeger HD, Schackert HK: Involvement of hMSH6 in the development of hereditary and sporadic colorectal cancer revealed by immunostaining is based on germline mutations, but rarely on somatic inactivation. Int J Cancer 2002;97:643–648.
35.
Kolodner RD, Hall NR, Lipford J, Kane MF, Morrison PT, Finan PJ, Burn J, Chapman P, Earabino C, Merchant E: Structure of the human MLH1 locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations. Cancer Res 1995;55:242–248.
36.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356–362.
37.
Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, Eng C, Parsons R: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16:64–67.
38.
Seitz S, Wassmuth P, Plaschke J, Schackert HK, Karsten U, Santibanez-Koref MF, Pankow H, Schlag PM, Scherneck S: Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines. Genes Chromosomes Cancer 2003;37:29–35.
39.
Kraus JA, Lamszus K, Glesmann N, Beck M, Wolter M, Sabel M, Krex D, Klockgether T, Reifenberger G, Schlegel: Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol (Berl) 2001;101:311–320.
40.
Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James D: Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J Neuropathol Exp Neurol 1995;54:57–64.
41.
Whitehall VL, Walsh MD, Young J, Leggett A, Jass JR: Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001;61:827–830.
42.
Kambara T, Matsubara N, Nakagawa H, Notohara K, Nagasaka T, Yoshino T, Hisozaki H, Sharp G, Shimizu K, Jass J, Tanaka N: High frequency of low-level microsatellite instability in early colorectal cancer. Cancer Res 2001;61:7743–7746.
43.
Dams E, van der Kelft EJ, Martin JJ, Verlooy J, Willems PJ: Instability of microsatellites in human gliomas. Cancer Res 1995;55:1547–1549.
44.
Zhu JJ, Guo SZ, Beggs AH, Muruyama, T, Santarius T, Dashner K, Olsen N, Wu J, Black PM: Microsatellite instability analysis of primary human brain tumors. Oncogene 1996;12:1417–1423.
45.
Izumoto S, Arita N, Ohnishi T, Hiraga S, Taki T, Tomita N, Ohue M, Hayakawa T: Microsatellite instability and mutated transforming growth factor-β receptor gene in gliomas. Cancer Lett 1997;112:251–256.
46.
Sobrido MJ, Rodriguez P, Barros F, Forteza J, Carracedo A, Lema M: Low frequency of replication errors in primary nervous system tumors. J Neurol Neurosurg Psychiatry 2000;69:369–375.
47.
Alonso M, Hamelin R, Kim M, Porwancher K, Sung T, Parhar P, Miler DC, Newcomb EW: Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 2001;61:2124–2128.
48.
Peraud A, Watanabe K, Schwechheimer K, Yonekawa Y, Kleihues P, Ohgaki H: Genetic profile of the giant cell glioblastoma. Lab Invest 1999;79:123–129.
49.
Wu MS, Sheu JC, Shun CT, Lee WJ, Wang JT, Wang TH, Cheng AL, Lin JT: Infrequent hMSH2 mutations in sporadic gastric adenocarcinoma with microsatellite instability. Cancer Lett 1997;112:161–166.
50.
Katabuchi H, van Rees B, Lambers AR, Ronnett BM, Blazes MS, Leach FS, Cho KR, Hedrick L: Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res 1995;55:5556–5560.
51.
Nicolaides NC, Littman SJ, Modrich P, Kinzler KW, Vogelstein B: A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. Mol Cell Biol 1998;18:1635–1641.
52.
Marra G, Iaccarino I, Lettieri T, Roscilli G, Delmastro P, Jiricny J: Mismatch repair deficiency associated with overexpression of the MSH3 gene. Proc Natl Acad Sci USA 1998;95:8568–8573.
53.
Hui AB, Lo KW, Yin XL, Poon WS, Ng HK: Detection of multiple gene amplifications in glioblastoma multiforme using array-based comparative genomic hybridization. Lab Invest 2001;81:717–723.
54.
Mao X, Hamoudi RA: Molecular and cytogenetic analysis of glioblastoma multiforme. Cancer Genet Cytogenet 2000;122:87–92.
55.
Meyer-Puttlitz B, Hayashi Y, Waha A, Rollbrocker B, Boström J, Wiestler O, Louis DN, Reifenberger G, von Deimling A: Molecular genetic analysis of giant cell glioblastomas. Am J Pathol 1997;151:853–857.
56.
Leung SY, Yuen ST, Chan TL, Chan ASY, Ho JWC, Kwan K, Fan YW, Hung KN, Chung LP, Wyllie AH: Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation. Oncogene 2000;19:4079–4083.
57.
Bussaglia E, del Rio E, Matias-Guiu X, Prat J: PTEN mutations in endometrial carcinomas: A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312–317.
58.
Lefevre SH, Vogt N, Dutrillaux AM, Chauveinc L, Stoppa-Lyonnet D, Doz F, Desjardins L, Dutrillaux B, Chevillard S, Malfoy B: Genome instability in secondary solid tumors developing after radiotherapy of bilateral retinoblastoma. Oncogene 2001;20:8092–8099.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.